Latest Conference Articles

Sessions focuses on new diabetes treatment options.

Two new fixed-dose basal/GLP-1 receptor-agonist agents, Soliqua 100/33 (Sanofi) and Xultophy 100/3.6 (Novo Nordisk), were approved by the FDA in November 2016.

In this clip, Jeffrey Fudin, PharmD, who spoke at APHA 2017 on opioid tapering, discusses options pharmacists should consider when tapering patients.

In this clip, Jeffrey Fudin, PharmD, discusses available options in abuse-deterrent formulations of opioids.

APhA is about to kick off and we'll be there all weekend covering it live!

At the American College of Cardiology Scientific Session, a study of prescriptions for PCSK9 inhibitors confirms what doctors say about trying to get their patients access to the cholesterol drug.

A double dose of inclisiran reduced LDL cholesterol up to 52.6%.

Discrepancies found when comparing real-world findings to clinical trial findings.

Researchers sought to change the volume of fatty deposits in a coronary artery that was at least 30% blocked.

Study compares common treatment options to prevent recurrent venous thromboembolism.

Complications associated with left main bifurcation can impact stent choice.

A multi-faceted screening approach could prevent sudden cardiac deaths in young athletes.

Including warning labels may improve healthy eating habits.

A study led by UC Irvine and Duke University, presented at the 2017 American Academy of Pain Medicine meeting in Orlando, examined the association between opioid therapy and melanoma progression in patients diagnosed with the disease.

Americans admitted to the hospital for heart failure have a 6% higher risk of dying than patients admitted in the spring.

Treatments have only increased 10% in hospitals nationwide over the past decade.

A self-expanding transcatheter aortic valve replacement (TAVR) procedure was just as effective as surgery in intermediate risk patients.

The Patient Navigator Program reduced readmission for heart attack or heart failure patients by 81.3%.

At the American Academy of Pain Medicine’s 2017 Annual Meeting, survey results were presented that revealed the implications of naloxone use in real-world experiences with the recently approved intranasal naloxone formulation.

Evolocumab offers a 25% reduction in cardiovascular (CV) death, heart attack, or stroke after the first year.

Small case report found an association between the Zika virus and cardiovascular complications.

FOURIER trial meets its primary composite endpoint reducing cardiovascular risk factors.

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.

The meeting theme this year, Pain as a Public Health Issue, emphasizes the extent to which pain affects the US population, with more than 100 million Americans suffering from pain.

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.

Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.